Originally published Thursday, February 28, 2008 at 12:00 AM
$19 million for biotech startup PhaseRx
Venture capitalists have agreed to nurture PhaseRx, a nascent Seattle biotech, with funding of up to $19 million to pursue a pioneering technique that could help turn off harmful genes.
Seattle Times business reporter
Venture capitalists have agreed to nurture PhaseRx, a nascent Seattle biotech, with funding of up to $19 million to pursue a pioneering technique that could help turn off harmful genes.
The financing, led by ARCH Venture Partners, 5AM Ventures and Versant Ventures, starts with a $4 million upfront investment.
The remainder will be available upon hitting some research milestones, such as putting the theory behind its technology into practice, and reaching certain business objectives the firm declined to disclose.
The rest of the investment could come in the next 24 months, said founder Bob Overell.
PhaseRx seeks to develop a way to deliver therapies based on siRNA, or small interfering RNA, a technique that allows genes linked to maladies to be switched off.
That research field is one of the hottest in the biotechnology sector, said David Miller, an analyst with Biotech Stock Research. In late 2006, pharma giant Merck paid $1.1 billion for Sirna Therapeutics, triggering a "land rush" on small private companies working in the field, Miller said. Interest in this new field is "huge," he said.
Another local biotech, Nastech Pharmaceutical, aims to spin off its RNA interference research program into a separate firm. One of its former executives, Paul Johnson, is the founding chief scientific officer of PhaseRx.
PhaseRx was put together by Overell, a former Frazier Healthcare Ventures partner who now heads Foundation BioVentures in Seattle. Other founders include University of Washington researchers Patrick Stayton and Allan Hoffman, and Oliver Press of the Fred Hutchinson Cancer Research Center.
Despite the RNA interference hype, the technology has a long way to go, said Miller. "Nobody has figured out how to deliver an RNA-based drug in humans yet."
But PhaseRx founders are optimistic. They said in a statement that the polymer technology the company licensed from Stayton and Hoffman's laboratories at the UW "enables the effective delivery" of interfering RNA and other therapies into living animals.
This is the second local budding biotech recently funded by ARCH Ventures. The firm in November led a $12 million financing round for Fate Therapeutics, which seeks to develop stem-cell based therapies.
ARCH managing director Steven Gillis, a co-founder of Immunex and Corixa, will become PhaseRx's chairman.
Ángel González: 206-515-5644
Copyright © 2008 The Seattle Times Company
Brier Dudley: Handbook for Droid users
NEW - 10:33 PM
Plans call for Triangle to become West Seattle gateway
Chip companies may face a drawn-out recovery
Interface: Delve Networks helps publish and manage online videos

Mourners gather at KeyArena for slain officer's memorial
Mourners gathered at KeyArena for the memorial service of Seattle police Officer Timothy Brenton on November 6, 2009.
nwjobs

Post a comment

Michelle Goodman blogs about work/life balance.
How to tell your office you're gravely ill
Post a comment
nwautos

Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment
- Flags were key link to cop slaying, bombings
- Suspect shot as city mourns slain officer
- Bombs, guns found at home of suspect in Officer Brenton's slaying
- Briefs | Soccer: New Mexico suspends hair-pulling player Elizabeth Lambert
- How an underdog named Mike McGinn took City Hall
- 3 Cascade Mountain passes close due to snow; more rain, wind expected Sunday
- Huskies suffer another heartbreaking loss to UCLA
- The birth of 'Grunge,' in photos by Michael Lavine
- McGinn pulling away as late ballots come in
- Using anti-shooter tactics, civilian Army police officer brought down gunman
- U.S. House passes health plan
378 - Bombs, guns found at home of suspect in Officer Brenton's slaying
298 - Referendum 71 show's Washington's strategy for marriage equality is working
161 - Grading the game
161 - Beavers open as 10-point favorites against Huskies
94 - How an underdog named Mike McGinn took City Hall
94 - Sounders FC-Dynamo playoff Game 2 thread
81 - Fort Hood shooting suspect had shown troubling signs
75 - Game thread: Detroit Lions at Seattle Seahawks, Nov. 8
74 - Landmark health bill passes House on close vote
72
- Suspect shot as city mourns slain officer
- Flags were key link to cop slaying, bombings
- The birth of 'Grunge,' in photos by Michael Lavine
- Bombs, guns found at home of suspect in Officer Brenton's slaying
- 10 ways to take control of your health
- Tlingit heritage helps glass artist Preston Singletary break new ground
- 10 investing missteps to avoid
- How an underdog named Mike McGinn took City Hall
- How do innovators think?
- Danny Westneat | Lee the Horse Logger found slow wagon shrank tumor





